XmAb942 Phase 1 data supports best-in-class profile with 74-day half-life enabling Q12W SC dosing and low immunogenicity. The XENITH-UC Phase 2b blinded interim around YE26 is the next major catalyst. XmAb412 FIH start in 3Q26 adds pipeline optionality. Monitor for partnership interest given precedent valuations shown ($1.5B-$10B+).
Price Chart
Executive Summary
Xencor reported final Phase 1 data for XmAb942, an anti-TL1A antibody for IBD, showing a terminal half-life of 74.1 days, favorable safety, and low immunogenicity (0% neutralizing antibodies at target dose). The company also presented preclinical data for XmAb412, a TL1A x IL23p19 bispecific, with predicted human half-life of 60-70 days. Enrollment in the Phase 2b XENITH-UC study remains on track with a blinded interim analysis expected around year-end 2026 and primary endpoint results in 2H27.
Key Facts
- XmAb942 Phase 1 estimated terminal half-life of 74.1 days from pooled single-dose cohorts
- 0% neutralizing antibodies (NAb+) at XENITH-UC target dose regimen; 25% ADA+ at target dose
- 86% of patients predicted to achieve >99% TL1A inhibition at induction (Week 12) per QSP model
- 90% of patients predicted to achieve >90% TL1A inhibition at maintenance (Week 52) with Q12W SC dosing
- No serious or severe TEAEs; TEAE rates similar between XmAb942 (75%) and placebo (69%)
- XmAb412 predicted human half-life of 60-70 days; NHP half-life >20 days
- XmAb412 FIH study expected to begin 3Q26
- XENITH-UC Phase 2b enrolling ~220 patients; blinded interim analysis ~YE26, primary endpoint 2H27
- Cash position ~$611M as of Dec 31, 2025
Financial Impact
No financial data reported; clinical-stage biotech with ~$611M cash position
Risk Factors
- Phase 2b XENITH-UC results may not replicate Phase 1 PK/PD predictions
- Competitive landscape includes multiple first-gen anti-TL1A programs (afimkibart, tulisokibart, duvakitug) in Phase 3
- ADA incidence of 57% across all doses could impact long-term efficacy if neutralizing antibodies emerge
- No revenue-generating products; dependent on pipeline success and partnerships
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001326732-26-000036 |
| Document: xncr-20260504xexx992.htm | 0001326732-26-000036 |
| Document: xncr-20260504.htm | 0001326732-26-000036 |
| Document: 0001326732-26-000036-index-headers.html | 0001326732-26-000036 |
| Document: 0001326732-26-000036-index.html | 0001326732-26-000036 |
| Document: 0001326732-26-000036.txt | 0001326732-26-000036 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $20.00 $26.62 | ▲ +33.10% | ▲ +32.50% | $25.01 (+25.07%) |
Jun 17, 2026 15w ago | Insider Cluster | $12.64 $14.95 | ▲ +18.28% | ▲ +17.74% | $25.01 (+97.90%) |
Jun 15, 2026 15w ago | 144 | $12.21 $14.96 | ▲ +22.52% | ▲ +23.27% | $25.01 (+104.87%) |
Jun 15, 2026 15w ago | 144 | $12.21 $14.96 | ▲ +22.52% | ▲ +23.27% | $25.01 (+104.87%) |
May 6, 2026 21w ago | 8-K | $12.31 $11.42 | ▲ +7.23% | ▲ +10.37% | $25.01 (−103.21%) |
May 5, 2026 21w ago | 8-K | $12.85 $11.21 | ▼ −12.76% | ▼ −17.72% | $25.01 (+94.67%) |
Apr 27, 2026 22w ago | 8-K | $12.15 $11.63 | ▼ −4.28% | ▼ −9.75% | $25.01 (+105.88%) |
Mar 5, 2026 30w ago | Insider Cluster | $11.16 $12.81 | ▲ +14.78% | ▲ +18.57% | $25.01 (+124.15%) |
Mar 4, 2026 30w ago | 8-K | $11.16 $12.81 | ▼ −14.78% | ▼ −18.57% | $25.01 (−124.15%) |
Feb 25, 2026 31w ago | 8-K | $11.98 $12.40 | ▲ +3.51% | ▲ +8.74% | $25.01 (+108.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access